Dysregulation of the immune system and autoimmune processes play a key role in severe and long-term course of COVID-19 infections. Research has shown that autoantibodies against phospholipids, anti-cardiolipin and anti-beta-2-glycoprotein, may contribute significantly to COVID-19 related autoimmunity and disease severity. Understanding how these antibodies trigger the thrombotic manifestations of the disease is important to improve patient management and to understand the underlying pathophysiology of SARS-CoV-2 infection.
Doctors’ awareness of autoantibodies promoting COVID-19 disease and determination of these autoantibodies with reliable laboratory tests will benefit the patients.
